Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from J&J

Vacunados con J&J, reforzados con ARNm, y pensando en la tercera dosis

Sí, todos estamos agotados por la pandemia de covid. Desconcertados por los constantes cambios en la ciencia y en las directrices. Preocupados por la sucesión de nuevas y temibles variantes, cada una con su propio nombre, como los huracanes.

Tribune News Service

The Daily Biotech Pulse: Pfizer Begins Late-Stage Pediatric COVID Pill Study, Midatech And J&J Unit Expand R&D Collaboration, AbbVie-Alvotech Settle Humira Dispute

The Daily Biotech Pulse: Pfizer Begins Late-Stage Pediatric COVID Pill Study, Midatech And J&J Unit Expand R&D Collaboration, AbbVie-Alvotech Settle Humira Dispute

Here's a roundup of top developments in the biotech space over the last 24 hours.

Johnson and Johnson talcum powder cancer lawsuits expose history of human experimentation on Black prisoners

Johnson and Johnson talcum powder cancer lawsuits expose history of human experimentation on Black prisoners

Company tested ingredients on Black inmates for years near Philadelphia, documents show

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

To be 1 in a million: ‘Who thinks it’s going to be you?’

BEND, Ore. — Monica Melkonian wanted the Johnson & Johnson COVID-19 vaccine. It was only one shot and then she would be protected against the virus. So she was thrilled when the vaccination clinic at the Deschutes County Fair & Expo Center on April 7 had her first choice.

Tribune News Service

Johnson & Johnson Allowed To Move Ahead With Bankruptcy Strategy On Talc Lawsuits: WSJ

In a federal bankruptcy court in Trenton, New Jersey, Judge Michael Kaplan ruled in favor of Johnson & Johnson's (NYSE: JNJ) controversial bankruptcy filing meant to settle 38,000 claims alleging its talc-based products caused cancer.

J&J, distributors finalize $26B landmark opioid settlement

Drugmaker Johnson & Johnson and three major distributors have finalized a nationwide settlement over their role in the opioid addiction crisis

The Independent UK

The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel In Late March

inkl

Read news from The Economist, FT, and more,
with one subscription

Vaccinated people less likely to get long Covid than unvaccinated, new study shows

Vaccinated people less likely to get long Covid than unvaccinated, new study shows

Review finds those who have received two doses of Pfizer/BioNTech, AstraZeneca or Moderna vaccine, or one dose of single-shot J&J vaccine, half as likely to develop long Covid symptoms

The Independent UK

J&J starts trial on bankruptcy case under attack by Congress

The controversial Johnson & Johnson bankruptcy strategy that’s drawn the ire of Congress faces a fresh trial this week, with the consumer products giant arguing that settling billions of dollars of talc liabilities in a single case is better for cancer victims than fighting thousands of individual claims.

Tribune News Service

Johnson & Johnson faces push to force global ban on talc baby powder sales

Johnson & Johnson faces push to force global ban on talc baby powder sales

Move to hold shareholder vote follows withdrawal of product in US and Canada and lawsuits alleging link to cancer cases

The Guardian - UK

Johnson & Johnson recipients can get third COVID shot in San Francisco

SAN FRANCISCO — San Francisco health officials are allowing people who originally got the Johnson & Johnson COVID-19 vaccine to get a second booster shot — which would give them access to the same number of doses currently available to recipients of Pfizer-BioNTech or Moderna.

Los Angeles Times

The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study

The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study

Here's a roundup of top developments in the biotech space over the last 24 hours:

The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data

The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data

Here's a roundup of top developments in the biotech space over the last 24 hours.

1

Organisations

Johnson & Johnson

Sierra Oncology

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

372,548 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play